Navigation Links
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
Date:6/10/2011

ma GmbH), a novel, highly efficient and portable aerosol delivery system enabling more effective distribution in the lungs.

ARIKACE has been granted orphan drug status in the United States by the FDA, and has received an orphan drug designation in Europe by the European Medicines Agency for the treatment of Pseudomonas infections in patients with CF.  In addition, the Company recently filed for orphan drug designation for NTM lung infections in the United States and plans to do so in the European Union once the process is completed in the United States.

About The Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease.  The CF Foundation is a donor-supported nonprofit organization.  For more information, go to www.cff.org.

About eFlow® Technology and PARI Pharma

ARIKACE is delivered by an investigational eFlow® Nebulizer System developed by PARI Pharma and optimized specifically for ARIKACE.  The optimized, investigational eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of medication including liposomal formulations via a vibrating, perforated membrane that includes thousands of laser drilled holes.  Compared to other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible period of time.  eFlow® Technology is
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
2. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
4. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
5. VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
6. PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
7. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
8. HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting
9. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
10. Baxa Corporation Demonstrates End-to-End Environmental Stewardship
11. REMEDIAL II Trial of PLCs RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 About Duchenne muscular ... disease, which generally affects the male population. It ... The disease is caused due to mutations in ... of production of dystrophin (a protein essential for ... of dystrophin weakens muscle function, causes loss of ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... is a malignant condition characterized by increased production of ... affects B-lymphocytes and then it can spread to other ... at later stages because of the slow buildup of ... the malignancy spreads to the spleen, liver, and lymph ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... Xlumena, Inc., a privately-held provider of innovative technology ... that it has received CE Mark approval for its ... system that enables exchange-free access, tract dilation and delivery ... NAVIX will join the AXIOS Stent and Delivery System ...
... The Chinese Biopharmaceutical Association-USA (CBA) successfully held its 16 ... US.   With the theme of ... the conference drew nearly 500 attendees with ... exhibited at the conference, including Chinese leading biotech parks, ...
Cached Medicine Technology:Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 3
(Date:9/2/2015)... ... ... Sara Bleich, Ph.D., associate professor of health and policy ... recognized scholar on obesity prevention and control, has been selected for the prestigious ... graduate of Garrison Forest School, an all-girls’ independent school in Owings Mills, Md., ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... innovation and investment, announced the two leaders who will deliver keynote presentations at ... 3, at the Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... in the news recently following a decision by the Centers for Medicare & ... likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price ...
(Date:9/2/2015)... ... 2015 , ... Healtec® LLC hired Stanley H. Salot Jr. ... former Chief Operations Officer. Shaun Carpenter MD, FAPWCA, CWSP , co-founder and ... Stanley H. Salot Jr , our new President and CEO, has nearly forty ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Good health ... Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New ... donation to the foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA ...
Breaking Medicine News(10 mins):Health News:Dr. Sara Bleich, Garrison Forest Graduate, Selected for 2015-16 Class of White House Fellows 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:Healtec® Announces Executive Leadership Change 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3
... Institution in Washington, D.C. has joined Arizona State University ... sustaining a biodiverse planet. On Feb. 12, Secretary Wayne ... M. Crow launched a global classroom with one ... the tropical landscapes of Panama. The partnership ...
... , ... a leading provider of consumer driven telemedicine solutions announced that it closed a $5 million ... ... provider of consumer driven telemedicine solutions that drive down healthcare costs, announced that it closed ...
... ... to grow sales and reduce its impact on the environment. While renewing ... Foods, the largest Home Food service company in America, discovered they had ... once again measured and offset 100% of Service Foods’ scope 1 and ...
... ... year over year revenue growth. Unlimited use data room offer is the key driver. ... (PRWEB) February 16, 2010 -- ... secure extranets today announced that it had year over year revenue growth of 237%., , ...
... , , ... Bluestar Silicones is,launching a new line of TCS 7560 and ... lingerie and medical applications (support,stockings and medical equipment). These two ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20100216/377913 ) ...
... ... in compliance with SAS 70 recommended best practices related to internal controls. , ... Bellevue, WA (PRWEB) Feb. ... announced today that the company has received its completed SAS 70 Type II report. ...
Cached Medicine News:Health News:Smithsonian Institution, Arizona State University announce education and research partnership 2Health News:Consult A Doctor Closes $5 Million VC Round 2Health News:Consult A Doctor Closes $5 Million VC Round 3Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 2Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 3Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 2Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 3Health News:Firmex Achieves 237% Annual Revenue Growth Despite Tough M&A Environment in 2009 4Health News:Bluestar Silicones Launches a New Range of Silbione(R) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications 2Health News:Corporate Wellness Firm Limeade Receives SAS 70 Type II Report 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: